Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src [S]

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 2, 2010, Pages 373-381

  Jaganathan, Soumya ^a   Yue, Peibin ^a   Turkson, James ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 4 [2 [[(4 METHYLBENZENE)SULFONYL]OXY]ACETAMIDO]BENZOIC ACID; ANTINEOPLASTIC AGENT; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; JANUS KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ONCOGENE SRC; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; ONCOGENE PROTEIN V-AKT; PANCREATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 77951030170     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.162669     Document Type: Article

References (36)

1. Burris H 3rd and Rocha-Lima C (2008) New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13:289-298.
2. Darnell JE (2005) Validating Stat3 in cancer therapy. Nat Med 11:595-596.
3. DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, and Freeman JW (2003) Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 22:7781-7795. (Pubitemid 37485537)
4. Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, and Dong YT (1998) Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 18:4613-4619. (Pubitemid 29042032)
5. Downward J, Parker P, and Waterfield MD (1984) Autophosphorylation sites on the epidermal growth factor receptor. Nature 311:483-485. (Pubitemid 14035459)
6. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et al. (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513. (Pubitemid 32531347)
7. Gouilleux F, Moritz D, Humar M, Moriggl R, Berchtold S, and Groner B (1995) Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor. Endocrinology 136:5700-5708.
8. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, et al. (2002) Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 21:8804-8816. (Pubitemid 36132401)
9. Johnson FM, Saigal B, Tran H, and Donato NJ (2007) Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 13:4233-4244. (Pubitemid 47105988)
10. Korc M, Meltzer P, and Trent J (1986) Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 83:5141-5144. (Pubitemid 16051332)
11. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Lührs H, Friess H, Büchler MW, and Adler G (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243:503-508. (Pubitemid 28414054)
12. Mahtouk K, Hose D, Rème T, De Vos J, Jourdan M, Moreaux J, Fiol G, Raab M, Jourdan E, Grau V, et al. (2005) Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 24:3512-3524. (Pubitemid 40756252)
13. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, and Jove R (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65:9185-9189. (Pubitemid 41507982)
14. Ouyang H, Mou Lj, Luk C, Liu N, Karaskova J, Squire J, and Tsao MS (2000) Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157:1623-1631.
15. Philip PA (2008) Targeted therapies for pancreatic cancer. Gastrointest Cancer Res 2 (Suppl 2):S16-S19.
16. Saif MW (2008) Erlotinib: the first biologic in the management of pancreatic cancer. Exp Opin Pharmacother 9:1595-1607. (Pubitemid 352005919)
17. Salomon DS, Brandt R, Ciardiello F, and Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
18. Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M, Wiedenmann B, and Rosewicz S (2003) Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125:891-905. (Pubitemid 37070705)
19. Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB, and Rosen J (1995) Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci USA 92:3041-3045.
20. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, and Pazdur R (2007) Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 21:1696-1706; discussion 1706-1709, 1712, 1715.
21. Shao H, Cheng HY, Cook RG, and Tweardy DJ (2003) Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63:3923-3930. (Pubitemid 36917907)
22. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, et al. (2007a) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104:7391-7396. (Pubitemid 47185916)
23. Siddiquee KA, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Schroeck C, Sebti SM, Jove R, Hamilton AD, et al. (2007b) An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2:787-798. (Pubitemid 351166054)
24. Tice DA, Biscardi JS, Nickles AL, and Parsons SJ (1999) Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96:1415-1420. (Pubitemid 29098465)
25. Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, and Tanaka M (2003) Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 201:107-116. (Pubitemid 37298003)
26. Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC, Watowich SS, Chiao PJ, et al. (2006) Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis 9:101-110.
27. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, and Gallick GE (2006) Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 168:962-972.
28. Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Exp Opin Ther Targets 8:409-422. (Pubitemid 39359648)
29. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, and Jove R (1998) Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545-2552. (Pubitemid 28183424)
30. Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, and Arnoletti JP (2007) EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res 143:20-26. (Pubitemid 47562457)
31. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K, and Mochizuki H (2004) The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29:e1-e8.
32. Wagner BJ, Hayes TE, Hoban CJ, and Cochran BH (1990) The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J 9:4477-4484.
33. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, and Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754.
34. Yue P and Turkson J (2009) Targeting STAT3 in cancer: how successful are we? Exp Opin Invest Drugs 18:45-56.
35. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, Krolewski JJ, Medveczky P, and Jove R (2000) Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 275:24935-24944. (Pubitemid 30626601)
36. Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L, and Freeman JW (2008) Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor β-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 68:4221-4228.